top of page
Recruiting: Open

Influenza Vaccine Trial

Clinical Trial

Vaccine
Description

  • Randomised double-blinded study

  • 4 treatment groups for each age group (18-49 and 60+)

    • "Trivalent Darwin" formulation which includes A(H1N1), A(H3N2), and B/Victoria lineage strains 

    • "Trivalent Darwin" formulation with an additional antigenically distinct A(H3N2) strain

    • "Trivalent Darwin" formulation with double the H3 antigen

    • “Trivalent Tasmania” formulation composed of A(H1N1), B/Victoria lineage strains and an antigenically distinct A(H3N2) strain.

Trial length

1 month

Participant age

Participant ages can range from 60+

Patient eligibility

  • Healthy adult participants within the eligible age ranges

  • Participants must not have received an influenza vaccine in 2024

  • Participants must not have had a diagnosis of influenza within the past 12 months

  • Female participants must NOT be pregnant 

  • Female participants must NOT be breastfeeding

  • No history of immunosuppressive or immunodeficient conditions

2 onsite visits as well as 1 scheduled safety phone call is required from participants

​

*Travel is reimbursed for each visit

Follow-up inclusions

Objectives

To evaluate the safety and immunogenicity of an influenza vaccine formulation containing an additional H3 antigen.

Interested in participating?

Send us a message or give us a call here

Got questions?

Read our common queries about clinical trials, participation processes, safety measures, and more.

Get in touch with us

Our friendly team would love to hear from you! 

bottom of page